MedSchool: Ace Your OSCEsThe Medical Company
GET - On the App Store
Drug Guide


    IV infusion
    • Mechanism of Action
    • Contains a monoclonal antibody directed toward HER2 (trastuzumab), linked to a chemotherapeutic agent (DM1), allowing for targeted delivery of cytotoxic chemotherapy to HER2-positive tumour cells.
      Trastuzumab inhibits HER2 signalling pathways resulting in cell cycle arrest, and also mediates antibody-dependent cell-mediated cytotoxicity.
      DM1 is a cytotoxic agent that binds to tubulin, preventing polymerisation and resulting in cell cycle arrest in the G2/M phase.

Clinical Use

    • Indication
    • HER2-positive metastatic breast cancer refractory to trastuzumab.
    • Adverse Effects
Want more info like this?
  • Your electronic clinical medicine handbook
  • Guides to help pass your exams
  • Tools every medical student needs
  • Quick diagrams to have the answers, fast
  • Quizzes to test your knowledge
Sign Up Now